The resubmission of the BLA for accelerated FDA approval, especially after positive interactions, is a strong indicator of Mesoblast's confidence in their product and its potential market impact. This development is likely to be viewed positively by investors, as it not only demonstrates progress in the company's pipeline but also increases the likelihood of a successful product launch in the near term. Given the regulatory milestone and its implications for Mesoblast's growth, this news is highly relevant and important for investors, with a high confidence level in the analysis based on the positive Q3 interactions reported.